A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS. Vivos Inc. (the “Company,” “we,” “us,” “our”) is a radiation oncology medical device company engaged in the development of its yttrium-90 (“Y-90”) based precision radionuclide therapy device, RadioGel™, for the treatment of non-resectable tumors, now trademarked as Precision Radionuclide TherapyTM. A prominent team of radiochemists, scientists, and engineers, collaborating with strategic partners, including national laboratories, universities, and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. In 2013, the United States Food and Drug Administration (“FDA”) issued the determination that RadioGel™ is a device for human therapy for non-resectable cancers in humans. This should result in a faster path than a drug for final approval.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 49K | 0 | 0 | 0 | - | - |
| Net Income | -3.0M | -2.9M | -2.9M | -2.5M | -2.5M | -957K |
| EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.00 |
| Free Cash Flow | 0 | -1.7M | -1.3M | -1.1M | -964K | -876K |
| ROIC | -94.0% | - | -161.6% | - | -120.9% | -56.7% |
| Gross Margin | -127.4% | 0.0% | 0.0% | 0.0% | - | - |
| Debt/Equity | 0.00 | - | 0.18 | - | 0.07 | 6.71 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | - | - |
| Operating Income | -2.7M | -2.6M | -2.8M | -2.5M | -2.5M | -673K |
| Operating Margin | -5617.1% | 0.0% | 0.0% | 0.0% | - | - |
| ROE | -137.9% | - | -212.1% | - | -172.3% | -2987.4% |
| Shares Outstanding | 455M | 291M | 289M | 247M | 253M | 344M |
VIVOS INC passes 0 of 9 quality checks, indicating weak fundamentals.
VIVOS INC (RDGL) has a 5-year average return on invested capital (ROIC) of -113.1%. This is below average and may indicate limited pricing power.
VIVOS INC (RDGL) has a market capitalization of $32M. It is classified as a small-cap stock.
VIVOS INC (RDGL) does not currently pay a regular dividend.
VIVOS INC (RDGL) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
VIVOS INC (RDGL) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
VIVOS INC (RDGL) reported earnings per share (EPS) of $-0.01 in its most recent fiscal year.
The Ledger Terminal provides 14 years of financial data for VIVOS INC (RDGL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.